Low expression of miR-381 is a favorite prognosis factor and enhances the chemosensitivity of osteosarcoma

Osteosarcoma (OS) is the most common primary bone malignancy with a poor prognosis for all races and both sexes. In this study, we found that miR-381 is a positive prognosis factor for OS patients that OS patients with a low expression of miR-381 had a longer survival time after surgical interventio...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yunchao, Zhao, Chunhua, Yu, Zhibin, Chen, Jiarui, She, Xiaoling, Li, Peiyao, Liu, Changhong, Zhang, Yan, Feng, Jianbo, Fu, Haijuan, Wang, Bing, Kuang, Lei, Li, Lei, Lv, Guohua, Wu, Minghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356575/
https://www.ncbi.nlm.nih.gov/pubmed/27612424
http://dx.doi.org/10.18632/oncotarget.11861
Descripción
Sumario:Osteosarcoma (OS) is the most common primary bone malignancy with a poor prognosis for all races and both sexes. In this study, we found that miR-381 is a positive prognosis factor for OS patients that OS patients with a low expression of miR-381 had a longer survival time after surgical intervention, and miR-381 expression promotes MG-63 cell proliferation and cell invasion ability. Our results also showed a strong negative correlation between the expression of miR-381 and LRRC4 (brain relative specific expression gene) in OS tissues. This demonstrated that LRRC4 is a direct target gene of miR-381, and suppressing the expression of miR-381 increases the sensitivity of OS cells to chemotherapeutic drugs through the LRRC4-mediated mTOR pathway. In summary, miR-381 is an important biomarker in directing therapeutic intervention and predicting prognosis in OS patients.

Ejemplares similares